Urban Edge Properties (UE) Stock News

Uranium Energy Corp. (UEC) reported fiscal Q4 production of 82,744 pounds, up 157% sequentially, as it expanded operations across Wyoming and Texas. The company exceeded revenue expectations at $17.05 million but posted a wider-than-expected loss. UEC is scaling capacity at Christensen Ranch, ramping up Burke Hollow operations, and advancing Ludeman development while maintaining an unhedged uranium price exposure strategy. The company declined to provide fiscal 2027 guidance due to regulatory approval timing uncertainties.

Palisade Bio announced that its lead program PALI-2108, an oral PDE4 inhibitor prodrug, will be featured in four presentations at UEG Week 2026 in Barcelona. The presentations will showcase Phase 1b findings in fibrostenotic Crohn's disease, early clinical activity in ulcerative colitis, favorable safety and tolerability, gut-targeted exposure, and a biomarker to predict treatment response. PALI-2108 is advancing into Phase 2 clinical development for both ulcerative colitis and Crohn's disease.

A class action lawsuit has been filed against Wise Group plc (NASDAQ: WSE) for allegedly making false and misleading statements about its regulatory risks, particularly regarding anti-money laundering and terrorism financing prevention efforts ahead of its NASDAQ debut. Investors who purchased Wise securities between May 11, 2026 and July 23, 2026 have until September 29, 2026 to apply as lead plaintiffs.

Uranium Energy (UEC) is expected to report $9 million in Q4 revenues versus nil a year ago, but still post a loss of four cents per share. While uranium prices rose 16% year-over-year, higher operating, exploration, and development costs are expected to offset revenue gains. The company's shares have declined 18.1% over the past year.

Nucor stock declined 1.85% on September 14, 2026, underperforming the S&P 500's 0.48% loss. Over the past month, NUE shares fell 3.53% while the Basic Materials sector gained 0.06%. Despite the recent weakness, analysts project strong earnings growth with Q3 EPS expected at $5.58 (up 112% YoY) and full-year earnings of $18.52 per share (up 140% YoY). The stock trades at a Forward P/E of 14.01, below its industry average, and holds a Zacks Rank #3 (Hold) rating.

A class action lawsuit has been filed against FuelCell Energy, Inc. alleging the company made false and misleading statements regarding its manufacturing capacity, production rates under a capital equipment purchase agreement with Fit Energy, and profitability. The lawsuit covers securities purchased between June 24, 2026 and September 1, 2026. Investors can apply to be lead plaintiff until November 10, 2026.

RCI Banque (operating as Mobilize Financial Services) successfully priced a €1.25 billion dual-tranche bond offering on September 14, 2026, comprising a €750 million February 2031 bond at 4.625% coupon and a €500 million November 2033 bond at 5.00% coupon. The issuance was well-received by investors, with the shorter tranche attracting €1.6 billion in demand and the longer tranche generating €1.1 billion in orders.

Bernstein Liebhard LLP has announced multiple shareholder class action lawsuits against FuelCell Energy, Lincoln Educational Services Corporation, and Primoris Services Corporation. The lawsuits allege that these companies made materially false and misleading statements regarding their business operations, growth prospects, and financial stability, resulting in artificially inflated stock prices and significant investor losses during their respective class periods.

Nucor stock declined 1.79% on September 8, 2026, underperforming the S&P 500's 0.58% loss and lagging the Basic Materials sector. Despite strong earnings projections showing 107.60% EPS growth and 22.4% revenue growth for the upcoming quarter, the stock has lost 4.93% over the past month. Nucor holds a Zacks Rank #3 (Hold) with a Forward P/E of 14.54, slightly above its industry average.

Sky Blue Cinematix has been appointed as the exclusive worldwide brand-integration partner for two upcoming feature films from Tested Films: the action thriller 'Habeas Corpus' and the neo-noir romantic mystery 'Blurred', both directed by Ben Cookson. The partnership will connect international brands with these theatrical productions through in-film integration across all territories.

Kenvue Inc. (KVUE) demonstrated improved profitability in the first half of 2026, with adjusted operating margins rising 180 basis points to 23.1% and earnings climbing 18.9%, driven primarily by cost-cutting initiatives. However, organic sales growth remained modest at 1.2%, with the Self Care segment struggling while Skin Health and Beauty showed stronger performance. The company faces headwinds from tariffs, inflation, and $8.5 billion in debt, with a pending merger with Kimberly-Clark expected to close in Q4 2026.

Law firm Kirby McInerney LLP is investigating FuelCell Energy for potential securities fraud following the company's disclosure of $17 million in inventory charges and losses on its Fit Energy agreement. FuelCell revealed that product costs and manufacturing overhead exceed contractual pricing, causing the stock to fall 15.7% to $14.40 per share on September 2, 2026.

Revolution Medicines announced publication of Phase 1/2 clinical trial data for RASONQUE (daraxonrasib) in previously treated RAS mutant non-small cell lung cancer in the New England Journal of Medicine. The trial showed a 42% objective response rate and 16.0 months median overall survival in a docetaxel-naïve subgroup, with a manageable safety profile. Results support the ongoing Phase 3 RASolve 301 trial.

WisdomTree Multi Asset Issuer has announced an amendment to the Daily Swap Rate for its WisdomTree Silver 3x Daily Leveraged Securities, effective 1 December 2026. The rate will decrease from 0.01248% to 0.00692%, with amendment documents becoming effective on 1 September 2026. BNP Paribas acts as the Swap Provider for this change.

Onco360, the nation's leading independent specialty pharmacy, has been selected as a pharmacy partner by Revolution Medicines for the launch of RASONQUE (daraxonrasib), a RAS GTPase inhibitor for metastatic pancreatic adenocarcinoma. The drug showed significant clinical benefits in the phase 3 RASolute-302 trial, with median PFS of 7.3 months and OS of 13.2 months in RAS G12 mutation patients compared to 3.5 months and 6.6 months respectively for chemotherapy.

The FDA has approved RASONQUE (daraxonrasib), developed by Revolution Medicines, as the first targeted RAS inhibitor for treating metastatic pancreatic adenocarcinoma in patients who have received prior systemic therapy or are not candidates for multiagent chemotherapy. In the Phase 3 RASolute 302 trial, RASONQUE reduced the risk of death by 60% compared to chemotherapy, with median overall survival of 13.2 months versus 6.7 months, and demonstrated manageable safety with improved quality of life measures.

Rosen Law Firm reminds GRAIL, Inc. investors who purchased stock between May 13, 2025 and February 19, 2026 of the August 4, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit alleges that GRAIL provided misleading statements about its NHS-Galleri trial results, concealing that the trial period was insufficient to demonstrate the primary endpoint of reducing Stage III-IV cancers.

FIFA has faced backlash from global soccer governing bodies over the proposal to allow private investment.

Ferrari N.V. announced Q2 2026 net revenues of €1,938 million (up 8% YoY), operating profit of €605 million with a 31.2% margin, and net profit of €463 million. The company raised its 2026 guidance citing stronger-than-expected personalizations and lower currency headwinds. The order book covers deliveries through 2027, with new model launches including the Ferrari Luce and 12Cilindri Manuale contributing to the company's most complete product lineup in history.

Law firm Robbins Geller has filed class action lawsuits against GRAIL, Inc., GPGI, Inc., and Wix.com Ltd., alleging that executives made false and misleading statements to investors. GRAIL investors can seek lead plaintiff status by August 4, 2026, following a 50% stock price decline after the company failed to achieve primary endpoints in its NHS-Galleri cancer screening trial.

Value Line, Inc. reported fiscal year 2026 net income of $21.63 million ($2.30 per share), up 4.6% from the prior year. The company declared a quarterly dividend of $0.35 per share, marking the 12th consecutive year of increases, with an annualized rate of $1.40 per share. Investment gains nearly doubled to $6.43 million, while liquid assets increased 11.7% to $86.47 million and shareholders' equity grew 8.2% to $107.89 million.

Following ARGAN's proposed merger with WDP announced on July 23, 2026, Standard & Poor's has placed ARGAN's 'BBB-' issuer credit rating on Positive CreditWatch, indicating a potential upgrade to 'BBB' upon merger completion in Q1 2027. The combined entity would benefit from increased scale, geographic diversification, reduced tenant concentration risk, and a stronger financial profile.

ESET researchers discovered 11 old Microsoft-signed UEFI shim bootloaders with decade-old vulnerabilities that allow attackers to bypass UEFI Secure Boot on most UEFI-based systems. The vulnerable binaries, found in versions 0.9 and below from various software packages including PC-diagnostic tools and Linux distributions, have been revoked by Microsoft. Attackers can exploit these to deploy malicious UEFI bootkits even on systems with Secure Boot enabled, regardless of installed OS.

LA21-CDC received grant support from Truist Foundation to expand its Small Business Sustainability Initiative, which provides Philadelphia entrepreneurs with coaching, business systems training, capital readiness support, and AI-powered business tools to strengthen operations and build long-term sustainability.

The European Commission has approved Sanofi's Cenrifki (tolebrutinib), a brain-penetrating Bruton tyrosine kinase inhibitor, for treating secondary progressive multiple sclerosis (SPMS) without relapses. The approval is based on the Phase 3 HERCULES trial, which demonstrated that Cenrifki significantly delayed disability progression. The drug will be commercially available in Germany this year, with careful risk management protocols due to identified hepatic safety concerns.

InnSuites Hospitality Trust (IHT) reported Fiscal Q1 2027 net income of $74,702, a $35,672 improvement year-over-year, with record hotel revenue of $2.2 million and combined occupancy reaching 85.37%. The company continues exploring diversification opportunities including a potential reverse merger, IBC Hotels independent hotel services, and investments in UniGen Power's clean energy technology.

BioAge Labs announced the first participant has been dosed in QUELL-CV, a Phase 2 proof-of-concept trial evaluating BGE-102, an oral NLRP3 inhibitor for cardiovascular risk reduction. The randomized, double-blind, placebo-controlled trial will enroll approximately 160 participants with obesity and elevated inflammation across three dose levels. Phase 1 results showed BGE-102 achieved median hsCRP reductions of 86% and was well tolerated. Topline data are anticipated in the second half of 2026, with an additional Phase 1b/2a trial in diabetic macular edema planned for mid-2026.

Delivered strong Q1 2026 comparable store sales growth 1 of 22.6% and total revenue growth of 37.0% Achieved a four-year high gross margin 1 of 67.4 %, an increase of 530 bps Expanded adjusted EBITDA margin 1 to 36.8 %, underscoring our luxury-inspired business model Continued successful expansion with new stores outperforming expectations Raised adjusted EBITDA margin guidance for Fiscal 2026 to 38.25%–39.50 % MONTRÉAL , June 16, 2026 /CNW/ - Groupe Dynamite Inc. ("Groupe Dynamite" or the "Company") (TSX: GRGD ) today reported its financial results for the fiscal year 2026's first quarter ended May 2, 2026. "Our first quarter results demonstrate the strength of our operating model and our ability to deliver profitable growth. Comparable store sales increased 22.6%, gross margin reached a four-year high, and adjusted EBITDA margin expanded to 36.8% of revenue, positioning ourselves alongside the world's most profitable fashion houses. We continue to strive to remain a highly productive specialty retailer with strong brands, exceptional unit economics, disciplined inventory management, attractive returns on capital, and a growth engine we have built over decades that continues to scale profitably," said Andrew Lutfy, Chief Executive Officer and Chair of the Board. "Q1 was a strong start to fiscal 2026. Across both GARAGE and DYNAMITE, customers responded positively to our assortments, marketing campaigns and the consistency of the experience we deliver across channels. Our real estate strategy continues to be a significant driver of growth, customer acquisition and profitability. By opening new locations in premium centers, optimizing our fleet and delivering a compelling in-store experience, we continue to drive significant productivity improvements across our store network. Most importantly, we continue to see strong customer engagement across both brands, reflected

Edward Smolyansky, largest shareholder and former COO of Lifeway Foods, criticizes the Board's governance, stating the poison pill was only terminated after ISS recommended voting against all directors. He highlights a pattern of reactive governance, the reversal of a board refresh process, and calls for shareholders to vote against incumbent directors at the June 17 Annual Meeting to register dissatisfaction with the Board's conduct.

SINGAPORE , June 8, 2026 /PRNewswire/ -- VinFast Auto Ltd. announced its unaudited financial results for the first quarter ended March 31, 2026. In the first quarter of 2026, VinFast ("the Company") delivered 58,577 electric vehicles, representing an increase of 61% from the same period last year. International markets accounted for approximately 8% of total deliveries during the quarter. In Vietnam, VinFast's EV deliveries in the first quarter of 2026 increased by 53% year over year. The Company maintained its position as the number one OEM in the domestic automotive market since September 2024. Southeast Asia and India continue to be key growth markets for VinFast. At the end of the first quarter of 2026, VinFast ranked #1 BEV brand in the Philippines, #4 in India and #8 in Indonesia. The Company also delivered 143,136 units of e-scooters and e-bikes in the first quarter, representing an increase of 219% from the first quarter of 2025. In March alone, VinFast received more than 135,000 e-scooter orders and shipped over 93,000 e-scooters to dealers in Vietnam. VinFast currently holds the leading position in Vietnam's electric motorcycle market and, in March, expanded its share of the overall motorcycle market (including both ... Full story available on Benzinga.com